Literature DB >> 2385739

SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up.

J G Worrall1, M L Snaith, J R Batchelor, D A Isenberg.   

Abstract

Clinical features and immunogenetics were assessed in 100 SLE patients attending a rheumatology clinic for periods ranging from six months to 11 years (mean five years). Five-year survival was 88 per cent. Joint problems (94 per cent), rash (90 per cent) and haematological abnormalities (89 per cent) were the most common clinical features; neuropsychiatric disturbance (45 per cent) and renal disease (29 per cent) were seen less frequently. A range of serological abnormalities was found, including antinuclear antibodies (98 per cent) and antibodies to phospholipids (38 per cent). Anti-Sm antibodies (7 per cent) showed a marked ethnic bias. Tissue typing confirmed the importance of genetic factors by demonstrating significant increases in A1, B8 and DR3 in white Caucasians. The composite phenotype A1,B8,DR3 was present in 35 per cent of white Caucasian patients with SLE. The A1,B8 phenotype was associated with a relative risk of 8.0 and B8,DR3 with a relative risk of 8.32.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2385739

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  21 in total

1.  Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center.

Authors:  M Funauchi; H Shimadzu; C Tamaki; T Yamagata; Y Nozaki; M Sugiyama; S Ikoma; K Kinoshita
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

2.  Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; Salvador Macías-Díaz; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Pamela Soto-Santillán; Beatriz Pérez-Romano; Erick A Jiménez-Herrera; Omar Guzmán-Ruiz; Alejandro Ruiz-Argüelles
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

3.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

4.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

5.  Systemic lupus erythematosus arising in a patient with chronic silicosis.

Authors:  K Ozoran; H Uçan; H Tutkak; N Caner; M Yücel
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

Review 6.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 7.  Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy.

Authors:  K K Jain
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 8.  Cognitive and emotional abnormalities in systemic lupus erythematosus: evidence for amygdala dysfunction.

Authors:  Philip Watson; Justin Storbeck; Paul Mattis; Meggan Mackay
Journal:  Neuropsychol Rev       Date:  2012-08-11       Impact factor: 7.444

9.  Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients.

Authors:  N D Hopkinson; M Doherty; R J Powell
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

10.  Anti-dsDNA and Sm autoantibodies in systemic lupus erythematosus.

Authors:  E Martínez-Cordero; E Martínez-Miranda; M C Negrete-García; A Padilla; D E Aguilar León
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.